Evidence map›Paper›PMID 41950297›Full record

ArticlePloS one2026

Deep learning for adaptive chemotherapy: A DDPG-based approach to optimizing tumor-immune dynamics.

Wenlang Zhu, Mingliu Zhu, Weiye Wang, Liang Xu, Jie Wu, Weiping Li, Ruru Ma, Lingli Cao

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenlang ZhuDepartment of Gastrointestinal Surgery, The First People's Hospital of Taicang City, Taicang Affiliated Hospital of Soochow University, Taicang, Jiangsu, China.
Mingliu ZhuSchool of Mathematical Sciences, Suzhou University of Science and Technology, Suzhou, China.
Weiye WangSchool of Artificial Intelligence and Computer Science, Jiangnan University, Wuxi, China.
Liang XuSchool of Artificial Intelligence and Computer Science, Jiangnan University, Wuxi, China.
Jie WuSchool of Artificial Intelligence and Computer Science, Jiangnan University, Wuxi, China.
Weiping LiDepartment of Gastrointestinal Surgery, The First People's Hospital of Taicang City, Taicang Affiliated Hospital of Soochow University, Taicang, Jiangsu, China.
Ruru MaSchool of Mathematical Sciences, Suzhou University of Science and Technology, Suzhou, China.
Lingli CaoDepartment of Obstetrics and Gynecology, The First People's Hospital of Taicang City, Taicang Affiliated Hospital of Soochow University, Taicang, Jiangsu, China.ORCID https://orcid.org/0009-0003-4598-7574

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this article, we propose a deep reinforcement learning based chemotherapy regulation framework to realize personalized and dynamic optimization of cancer treatment. We use a nonlinear dynamic system to model the dynamic evolution of the tumor microenvironment including tumor cell, normal cell and immune cell interactions, with drug concentration serving as the control input variable. The Deep Deterministic Policy Gradient (DDPG) algorithm makes agents can study optimal dosing strategy in a continuous space of movement to inhibit tumor growth effectively and minimize damage to normal tissues. To make the strategy more stable, Gauss noise is added to the model to simulate physiological oscillations and uncertainties in the treatment reaction. Experimental results show that it can control the growth of tumor in various initial scenarios and the accumulation of the drug concentration with high flexibility and safety. Our technique provides a feasible technical way for precision, low toxicity adaptive chemotherapy.

Indexed as

Antineoplastic AgentsDeep LearningNeoplasmsAdaptive AlgorithmsAlgorithmsHumansNonlinear DynamicsReinforcement Machine LearningTumor MicroenvironmentAntineoplastic Agents

Identifiers

PMID41950297
PMCPMC13061330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.